We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th:
Qifu Technology, Inc. (QFIN - Free Report) : This credit-tech platform principally in China which provides a comprehensive suite of technology services to assist financial institutions and consumers and SMEs in the loan lifecycle, ranging from borrower acquisition, preliminary credit assessment, fund matching and post-facilitation service, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 17.9% over the last 60 days.
CareTrust REIT (CTRE - Free Report) : This real estate investment trust which is primarily engaged in the ownership, acquisition and leasing of healthcare-related properties, has a Zacks Rank #1, and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.1% over the last 60 days.
Basilea Pharmaceutica (BPMUF - Free Report) : This commercial stage biopharmaceutical company which is developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer, has a Zacks Rank #1, and witnessed the Zacks Consensus Estimate for its current year earnings increasing 29.6% over the last 60 days.
Basilea Pharmaceutica’s shares gained 6.4% over the last three month compared with the S&P 500’s gain of 6.0%. The company possesses a Momentum Score of A.
Image: Bigstock
Best Momentum Stock to Buy for August 28th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th:
Qifu Technology, Inc. (QFIN - Free Report) : This credit-tech platform principally in China which provides a comprehensive suite of technology services to assist financial institutions and consumers and SMEs in the loan lifecycle, ranging from borrower acquisition, preliminary credit assessment, fund matching and post-facilitation service, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 17.9% over the last 60 days.
Qifu Technology, Inc. Price and Consensus
Qifu Technology, Inc. price-consensus-chart | Qifu Technology, Inc. Quote
Qifu Technology’s shares gained 29.2% over the last three month compared with the S&P 500’s gain of 6.0%. The company possesses a Momentum Score of A.
Qifu Technology, Inc. Price
Qifu Technology, Inc. price | Qifu Technology, Inc. Quote
CareTrust REIT (CTRE - Free Report) : This real estate investment trust which is primarily engaged in the ownership, acquisition and leasing of healthcare-related properties, has a Zacks Rank #1, and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.1% over the last 60 days.
CareTrust REIT, Inc. Price and Consensus
CareTrust REIT, Inc. price-consensus-chart | CareTrust REIT, Inc. Quote
CareTrust REIT’s shares gained 18.4% over the last three month compared with the S&P 500’s gain of 6.0%. The company possesses a Momentum Score of A.
CareTrust REIT, Inc. Price
CareTrust REIT, Inc. price | CareTrust REIT, Inc. Quote
Basilea Pharmaceutica (BPMUF - Free Report) : This commercial stage biopharmaceutical company which is developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer, has a Zacks Rank #1, and witnessed the Zacks Consensus Estimate for its current year earnings increasing 29.6% over the last 60 days.
Basilea Pharmaceutica AG Price and Consensus
Basilea Pharmaceutica AG price-consensus-chart | Basilea Pharmaceutica AG Quote
Basilea Pharmaceutica’s shares gained 6.4% over the last three month compared with the S&P 500’s gain of 6.0%. The company possesses a Momentum Score of A.
Basilea Pharmaceutica AG Price
Basilea Pharmaceutica AG price | Basilea Pharmaceutica AG Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.